SHANDONG JINCHENG PHARMACEUTICAL GROUP CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.66 CNY | +1.49% |
|
-6.34% | -6.00% |
| Sales 2022 | 3.51B 484M | Sales 2023 | 3.54B 488M | Capitalization | 6.34B 874M |
|---|---|---|---|---|---|
| Net income 2022 | 273M 37.67M | Net income 2023 | 175M 24.15M | EV / Sales 2022 | 2.43 x |
| Net cash position 2022 | 208M 28.73M | Net cash position 2023 | 471M 64.93M | EV / Sales 2023 | 1.66 x |
| P/E ratio 2022 |
32.1
x | P/E ratio 2023 |
37
x | Employees | 3,806 |
| Yield 2022 |
0.66% | Yield 2023 |
1.2% | Free-Float | 69.23% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.49% | ||
| 1 week | -6.34% | ||
| Current month | -6.34% | ||
| 1 month | -17.80% | ||
| 3 months | +1.69% | ||
| 6 months | -9.74% | ||
| Current year | -6.00% |
1 week
15.30
16.73
1 month
15.3019.42
Current year
10.8320.50
1 year
10.8321.60
3 years
10.8344.98
5 years
10.8344.98
10 years
10.8059.83
| Managers | Title | Age | Since |
|---|---|---|---|
Jia Quan Li
PSD | President | 52 | 08-01-31 |
Jing Liu
DFI | Director of Finance/CFO | 48 | - |
Geng Xiu Zheng
CTO | Chief Tech/Sci/R&D Officer | 60 | 03-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ye Qing Zhao
CHM | Chairman | 48 | 04-06-30 |
Jia Quan Li
PSD | President | 52 | 08-01-31 |
Geng Xiu Zheng
CTO | Chief Tech/Sci/R&D Officer | 60 | 03-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 32 M€ | +4.30% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 15.66 | +1.49% | 4,467,900 |
| 24-06-06 | 15.43 | -3.56% | 8,364,000 |
| 24-06-05 | 16 | -2.02% | 4,024,200 |
| 24-06-04 | 16.33 | -0.43% | 6,121,018 |
| 24-06-03 | 16.4 | -1.91% | 5,045,700 |
End-of-day quote Shenzhen S.E., June 06, 2024
More quotes
Shandong Jincheng Pharmaceutical Group Co Ltd, formerly Shandong Jincheng Pharmaceutical Co Ltd, is a China-based company mainly engaged in pharmaceutical manufacturing. The Company operates primarily through three segments. Intermediates segment mainly produces cephalosporin side chain pharmaceutical intermediates and other pharmaceutical and chemical products. Preparation segment focuses on the antimicrobial field and women's health technology. Specialty Active Pharmaceutical Ingredients segment includes biological specialty active pharmaceutical ingredients and chemical active pharmaceutical ingredients. The Company also operates other businesses.
Sector
Pharmaceuticals
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -6.00% | 820M | |
| +45.82% | 765B | |
| +40.95% | 632B | |
| -6.16% | 354B | |
| +19.86% | 331B | |
| +9.32% | 299B | |
| +18.45% | 248B | |
| +11.88% | 216B | |
| -0.78% | 219B | |
| +5.90% | 164B |
- Stock Market
- Equities
- 300233 Stock
